1、關(guān)于食管癌最新化療第一張，PPT共十五頁(yè)，創(chuàng)作于2022年6月化療原則T1aN0的食管癌不需術(shù)后輔助化療T1b（侵及粘膜下層）尤其分化差的鱗癌術(shù)后應(yīng)作適當(dāng)輔助化療II、III期最好行新輔助放化療或放療或化療IV期：放化療轉(zhuǎn)移：化療頸段環(huán)咽肌5cm以內(nèi)的食管癌：放化療第二張，PPT共十五頁(yè)，創(chuàng)作于2022年6月化療有效藥物及方案第三張，PPT共十五頁(yè)，創(chuàng)作于2022年6月Preoperative chemotherapy RTOG8911 FP+ surgery VS surgery alone R0切除率提高（64 vs 59%） 但 OS無(wú)差異MRCOEO2 2周期FP+surgery VS

2、 surgery alone總生存提高3.5月（16.8 VS 13.3）Meta分析 5年生存及DFS提高4%（small but significant）第四張，PPT共十五頁(yè)，創(chuàng)作于2022年6月Preoperative chemotherapyAbstract 180：Outcomes associated with T4 esophageal cancer3 (7.9%) pCR, 17 (44.7%) pPR, 18 (47.4%) NR R0 resections were accomplished in 37 (94.9%) 14 例術(shù)后復(fù)發(fā)：pCR 1 (7.1%), pPR

3、 6 (42.9%), NR 7 (50%) median time to recurrence of 19.5 (4-71) monthsPatients achieving a pCR had a 5-year overall and disease free survival of (43% and 47%), compared to pPR (30% and 21%) while there were no 5-year survivors in the NR cohort we have demonstrated that neoadjuvant therapy and down s

4、taging of T4 tumors leads to increased R0 resections and improvements in overall and disease free survival 第五張，PPT共十五頁(yè)，創(chuàng)作于2022年6月Preoperative chemotherapyAbstract 4060 ： Final results of feasibility study of neoadjuvant chemotherapy with DCF for clinical stage II/III esophageal squamous cell carcino

5、ma （Japan） RR 60%， pCR 22% most common grade 3 or 4 toxicities were neutropenia (83%), febrile neutropenia (2%), anorexia (7%), and stomatitis (5%). 第六張，PPT共十五頁(yè)，創(chuàng)作于2022年6月chemoradiationRTOG85-01 trial (randomized) 5-Fu+DDP RT +RT（50Gy） （ 60Gy） 中位生存 14月 9月 5年生存率 27% 0INT0123 trial 不同放療劑量聯(lián)合相同化療方案，中位生存

6、、2年生存率及局部復(fù)發(fā)率無(wú)統(tǒng)計(jì)學(xué)差異VS第七張，PPT共十五頁(yè)，創(chuàng)作于2022年6月chemoradiationAbstract 4034 （2011 ASCO） Phase II trial （Japan） RT 30Gy/3wks + S1 80mg/m2/d d1-14 DDP 70mg/m2 d8 S1 80mg/m2/d d1-14 DDP 70mg/m2 d82wks later第八張，PPT共十五頁(yè)，創(chuàng)作于2022年6月chemoradiationAbstract 4034 （2011 ASCO） Phase II trial（Japan） stage II III IV pat

7、ient 12 61 29 CR (%) 92 64 24 PR (%) 100 85 66 OS 100% 795d 369d 主要不良反應(yīng)：3/4度骨髓抑制（36/14%） 2度惡心嘔吐，口腔黏膜炎等第九張，PPT共十五頁(yè)，創(chuàng)作于2022年6月chemoradiationAbstract 4072 （2011 ASCO） （France） Chemoradiation with FOLFOX plus cetuximab in locally advanced cardia or esophageal cancer: Final results of a GERCOR phase II t

8、rial (ERaFOX). （Stage III） FOLFOX6 + C225 2周期 FOLFOX6+ C225 + RT（50.4Gy） （5-Fu 1800mg/m2/d1-2）第十張，PPT共十五頁(yè)，創(chuàng)作于2022年6月chemoradiationAbstract 4072 （2011 ASCO） Phase II trial（France） male/female 60/19 median age 63 (23-79) PS 0/1/ND 47/31/1 SCC/adeno/undifferentiated 53/25/1 esophagus/cardia 74/5 ORR (I

9、TT) was achieved in 61 pts (77.2%） median PFS/OS were 13.8/21.6 months. Most frequent grade 3-4 toxicities were: neutropenia (28.4%), dysphagia-esophagitis (13.5%), rash (10.8%) and allergy (8.9%). 第十一張，PPT共十五頁(yè)，創(chuàng)作于2022年6月Chemotherapy for metastatic diseaseFluoropyrimidine/platinum-based first-line c

10、hemotherapy in metastatic esophageal squamous cell carcinoma: Prognostic factor analysis in 239 patients（Abstract 4088，韓國(guó)）XP與FP方案 ORR，PFS,OS 無(wú)統(tǒng)計(jì)學(xué)差異ECOG2, albumin level 3.5g/dL and weight loss (10% of the weight loss for 3 months) at the time of chemotherapy were significantly associated with both worse PFS (P0.05) and OS (P0.05). 第十二張，PPT共十五頁(yè)，創(chuàng)作于2022年6月Target therapyToGA study 曲妥珠單抗+化療 VS 化療在Her-2過表達(dá)的胃-食管交界腺癌， OS 提高（13.5 VS 11.1 月）C225、特羅凱、貝伐單抗Phase II trial of sorafenib in esophageal (E) and gastroesophageal junction (GEJ) cancer: Response and protracted stable disease